2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 393-396
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, CLL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

298 Spatial architecture of the leukemic cell surface defines hypomethylating agent response in acute myeloid leukemia

Yi Chen, MD, PhD, Rongjia Deng, MD2, Elliot O Eton, BA3, JangKeun Kim4, Sebastian Fernando, MS5, Varun Saichandan Sudunagunta, B.A.6, Edna Marie Stewart, B.S., M.S.7, Stefan Petkov8, Michele Simonetti9, Christopher Mason10, Aaron Viny, MD, MS11
1 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
2 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
3 New York Genome Center, New York, New York, United States, Sandra and Edward Meyer Cancer Center, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, United States, Tri-Institutional MD-PhD Program, Weill Cornell Medicine, Rockefeller University, Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States
5 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
6 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
8 Pixelgen Technologies, Stockholm, Sweden
9 Pixelgen Technologies, Stockholm, Sweden
10 Weill Cornell Medicine, New York, New York, United States
11 Columbia Stem Cell Initiative, Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York, United States, Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
Background: Hypomethylating agents (HMAs) remain a backbone of AML therapy, yet only a minority of patients respond, and no biomarker reliably identifies responders pretreatment. Equally important, abundance-based flow cytometry cannot distinguish regenerating progenitors from residual leukemia among CD34+ cells following therapy. We hypothesized that therapeutic response is encoded in the spatial organization of surface proteins rather than antigen abundance alone.

Methods: We conducted a phase 1 trial of 6-thioguanine (6TG) plus decitabine in advanced myeloid neoplasms (n=12) and an expanded institutional cohort treated at the recommended dose (n=67). Longitudinal bone marrow samples from complete responders (CR) and nonresponders (NR) underwent single-cell spatial surface proteomic profiling using the Pixelgen Proximity Network Assay, resolving antigen abundance, clustering, and pairwise protein colocalization at single-cell resolution. To assess reproducibility across institutions, spatial signatures were evaluated in an independent cohort of HMA-refractory relapsed AML treated at a separate academic center (n=3) and profiled using a distinct antibody panel. Orthogonal long-read methylome profiling and RNA sequencing were performed to assess associated molecular programs.

Results: ORR was 58% (7/12) in the phase 1 study and 30% (20/67) in the expanded cohort, with prior HMA exposure in 45% of responders; two responding patients remain in remission more than 10 years later. Single-cell spatial proteomics resolved marrow into an annotated surface atlas in which CD34 measurements mirrored conventional immunophenotyping.

At baseline, the difference between responders and nonresponders was predominantly spatial and largely independent of antigen abundance (R~0), indicating a biologic layer invisible to conventional flow cytometry. Responding leukemias were organized around an MHC-I/B2M-centered interaction network, whereas resistant leukemias were dominated by HLA-II and CD44/CD43 adhesion-centered programs. Following therapy, responders underwent marked reorganization of the leukemic surface proteome. CD34+ blasts decreased approximately four-fold, while CD8 effector T cells, NK cells, erythroid cells, B cells, and granulocytes expanded. Responding blasts acquired differentiation-associated surface states, whereas resistant blasts retained stemness- and adhesion-associated programs. Longitudinally, responding marrow actively rewired its surface architecture, coordinately gaining MHC-I-, lipid raft-, and immune-associated interaction modules, while resistant AML remained topologically stable. Importantly, late-treatment CD34+ cells in responders displayed an MHC-I/B2M-centered, HSC-like topology, whereas CD34+ cells in resistant AML retained blast-like clustering patterns. These topological states distinguished regenerating hematopoiesis from residual leukemia despite comparable CD34 expression levels.

The independent HMA-refractory cohort reproduced the same MHC-I-associated and adhesion-centered organizational programs despite use of a distinct antibody panel, demonstrating robustness across institutions and experimental settings. Orthogonal methylome analyses identified enhancer-centered regulatory remodeling associated with response, supporting a shared cell-state axis underlying these spatial phenotypes.

Conclusions: The organization of the leukemic cell surface, rather than antigen abundance, distinguishes response from resistance to HMA-based therapy. Spatial topology identifies biologically and clinically meaningful AML cell states that are invisible to conventional flow cytometry, distinguishes regenerating hematopoiesis from residual leukemia, and provides a reproducible biomarker framework across institutions and antibody panels. These findings establish cell-surface topology as a new dimension of AML biology and a candidate platform for treatment response assessment and therapeutic target discovery.
Yi Chen, MD, PhD: No relevant conflicts of interest to declare.